{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T11:18:54Z","timestamp":1648984734765},"reference-count":31,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.3892\/ol.2017.5805","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T07:53:17Z","timestamp":1488786797000},"page":"3144-3150","source":"Crossref","is-referenced-by-count":0,"title":["Expression of excision repair cross-complementation group 1 and class III \u03b2-tubulin in thymic carcinoma"],"prefix":"10.3892","volume":"13","author":[{"given":"Katsuhiro","family":"Okuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Tatematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Haneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoki","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,3,6]]},"reference":[{"key":"key20180108113024_b1-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00000478-197706000-00002","article-title":"Squamous cell carcinoma of the thymus. An analysis of eight cases","volume":"1","author":"Shimosato","year":"1977","journal-title":"Am J Surg Pathol"},{"key":"key20180108113024_b2-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.athoracsur.2012.09.006","article-title":"Thymic carcinoma: A multivariate analysis of factors predictive of survival in 290 patients","volume":"95","author":"Weksler","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"key20180108113024_b3-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.athoracsur.2013.04.078","article-title":"Surgical treatment and prognosis of thymic squamous cell carcinoma: A retrospective analysis of 105 cases","volume":"96","author":"Zhao","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"key20180108113024_b4-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F","article-title":"Thymic carcinoma. A clinicopathologic study of 60 cases","volume":"67","author":"Suster","year":"1991","journal-title":"Cancer"},{"key":"key20180108113024_b5-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0022-5223(94)70112-1","article-title":"Thymic carcinoma. Ten year' experience in twenty patients","volume":"107","author":"Hsu","year":"1994","journal-title":"J Thorac Cardiovasc Surg"},{"key":"key20180108113024_b6-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejcts.2004.03.043","article-title":"Thymic carcinoma. Clinical institutional experience with 15 patients","volume":"26","author":"Takeda","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"key20180108113024_b7-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1097\/JTO.0b013e31822e71c0","article-title":"Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma","volume":"6","author":"Agatsuma","year":"2011","journal-title":"J Thorac Oncol"},{"key":"key20180108113024_b8-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/cncr.11606","article-title":"Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma","volume":"98","author":"Yoh","year":"2003","journal-title":"Cancer"},{"key":"key20180108113024_b9-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.lungcan.2011.05.013","article-title":"Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: Evaluation of efficacy and toxicity","volume":"74","author":"Okuma","year":"2011","journal-title":"Lung Cancer"},{"key":"key20180108113024_b10-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2007.05.016","article-title":"Multimodal treatment of thymic carcinoma: Report of nine cases","volume":"59","author":"Magois","year":"2008","journal-title":"Lung Cancer"},{"key":"key20180108113024_b11-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000082626","article-title":"Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma","volume":"50","author":"Oguri","year":"2004","journal-title":"Chemotherapy"},{"key":"key20180108113024_b12-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2014.11.006","article-title":"Pemetrexed in patients with thymic malignancies previously treated with chemotherapy","volume":"87","author":"Liang","year":"2015","journal-title":"Lung Cancer"},{"key":"key20180108113024_b13-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.lungcan.2010.09.004","article-title":"S-1 is an acrive anticancer agent for advanced thymic carcinoma","volume":"70","author":"Okuma","year":"2010","journal-title":"Lung Cancer"},{"key":"key20180108113024_b14-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/JTO.0b013e3181d0a4a7","article-title":"S-1 plus cisplatin chemotherapy with concurrent radiation for thymic basaloid carcinoma","volume":"5","author":"Tagawa","year":"2010","journal-title":"J Thorac Oncol"},{"key":"key20180108113024_b15-ol-0-0-5805","first-page":"959","article-title":"Excision repair cross complementing-group 1: Gene expression and platinum resistance","volume":"14","author":"Altaha","year":"2004","journal-title":"Int J Mol Med"},{"key":"key20180108113024_b16-ol-0-0-5805","first-page":"2286","article-title":"Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer","volume":"8","author":"Lord","year":"2002","journal-title":"Clin Cancer Res"},{"key":"key20180108113024_b17-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/JCO.1998.16.1.309","article-title":"ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy","volume":"16","author":"Metzger","year":"1998","journal-title":"J Clin Oncol"},{"key":"key20180108113024_b18-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/088307380301801205","article-title":"Class III beta-bululin isotype: A key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology","volume":"18","author":"Katsetos","year":"2003","journal-title":"J Child Neurol"},{"key":"key20180108113024_b19-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1247\/csf.18.173","article-title":"Removal of beta III isotype enhances taxol induced microtubule assembly","volume":"18","author":"Lu","year":"1993","journal-title":"Cell Struct Funct"},{"key":"key20180108113024_b20-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"12902","DOI":"10.1074\/jbc.M414477200","article-title":"BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability","volume":"280","author":"Kamath","year":"2005","journal-title":"J Biol Chem"},{"key":"key20180108113024_b21-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2008.02.021","article-title":"Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer","volume":"62","author":"Okuda","year":"2008","journal-title":"Lung Cancer"},{"key":"key20180108113024_b22-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their chlinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"key":"key20180108113024_b23-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"key20180108113024_b24-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"key20180108113024_b25-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2005.07.172","article-title":"Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The cancer and leukemia group B (study 9730)","volume":"23","author":"Lilenbaum","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108113024_b26-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180108113024_b27-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2009.03.031","article-title":"Efficacy of chemotheraoy with carboplatin and paclitaxel for unresectable thymic carcinoma","volume":"67","author":"Igawa","year":"2010","journal-title":"Lung Cancer"},{"key":"key20180108113024_b28-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jjco\/hyr089","article-title":"Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer","volume":"41","author":"Furugen","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"key20180108113024_b29-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann Oncol"},{"key":"key20180108113024_b30-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1517\/13543784.2010.504708","article-title":"Thymic carcinoma: Current and future therapeutic interventions","volume":"19","author":"Weiss","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"key20180108113024_b31-ol-0-0-5805","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/JTO.0b013e31820b9b35","article-title":"Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and \u03b2 III-tubulin in thymic epithelial tumors","volume":"6","author":"Kaira","year":"2011","journal-title":"J Thorac Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2017.5805\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T11:05:59Z","timestamp":1601723159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2017.5805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,6]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,3,6]]},"published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.3892\/ol.2017.5805"],"URL":"https:\/\/doi.org\/10.3892\/ol.2017.5805","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,6]]}}}